Barrow Robert's Form 4 filing
Definium Therapeutics, Inc. (DFTX) · filed Oct 25, 2022
- Accession no.
- 0000899243-22-034146
- Filed
- Oct 25, 2022
- Trade date
- Oct 25, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $3.39K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Barrow RobertCIK 0001897557 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2022 | Common Shares | SSaleDisposed | −1,207 | $2.81F2 | −$3,391.67 | 251,093 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The Common Shares were sold in multiple transactions, all at a price of $3.83 CAD Dollars. This represents the price in United States Dollars using the conversion rate on October 25, 2022.
Referenced by the price of 1 transaction in Table I.